Total revenue increased to over $92 million Net product revenue increased 34% year-over-year to over $91 million Recorlev net revenue...
Barchart Research What to Expect from XERS Earnings XERS Generated August 5, 2026 Current Price $8.11 EPS Estimate $$0.02 Consensus Rating Strong Buy Average Move 8.38% Xeris Built Momentum Through Q2,...
Conference Call to be Held at 8:30 a.m. ET
Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies,...
Chief Executive Officer John Shannon named Chair of the Board Marla Persky to transition to Lead Independent Director of the Board Board appoints Nerissa Kreher, M.D., effective July...
Patent expected to provide intellectual property protection for Keveyis through 2039 Reinforces Xeris’ commitment to the primary periodic paralysis community and the...
Eliminates approximately $23 million of debt, resulting in approximately $2 million in annual interest savings Principal to be paid in cash, remainder in common stock
Xeris Biopharma (NASDAQ:XERS) reported a sharp increase in first-quarter 2026 revenue and raised the low end of its full-year revenue outlook, citing strong demand for RECORLEV and continued execution...